Moderna Inc MRNA shares are trading higher by 7.0% at $158.42. The company announced today it has reached an agreement with Japan to supply an additional 70 million doses of its COVID-19 booster vaccine.
The strength could also possibly be due to a recent spike in COVID-19 cases in China, which could help lift vaccine sector sentiment.
Moderna shares also saw strength Monday after the company announced the first participant has been dosed in a clinical trial of an experimental HIV trimer mRNA vaccine.
According to Moderna, the primary hypothesis is that the soluble and membrane-bound HIV envelope trimer mRNA vaccines will be safe and well-tolerated by HIV-uninfected individuals and will elicit autologous neutralizing antibodies. Moderna says the trial is expected to enroll approximately 100 HIV-negative adults, aged 18 to 55 years.
Moderna has a 52-week high of $497.49 and a 52-week low of $117.34.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
